Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity
- PMID: 33358571
- DOI: 10.1016/j.trecan.2020.12.001
Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity
Abstract
Despite the dramatic advances in cancer research over the decades, effective therapeutic strategies are still urgently needed. Increasing evidence indicates that connective tissue growth factor (CTGF), a multifunctional signaling modulator, promotes cancer initiation, progression, and metastasis by regulating cell proliferation, migration, invasion, drug resistance, and epithelial-mesenchymal transition (EMT). CTGF is also involved in the tumor microenvironment in most of the nodes, including angiogenesis, inflammation, and cancer-associated fibroblast (CAF) activation. In this review, we comprehensively discuss the expression of CTGF and its regulation, oncogenic role, clinical relevance, targeting strategies, and therapeutic agents. Herein, we propose that CTGF is a promising cancer therapeutic target that could potentially improve the clinical outcomes of cancer patients.
Keywords: CTGF/CCN2; cancer; cellular function; connective tissue growth factor; targeted therapy; tumor microenvironment.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
Epithelial derived CTGF promotes breast tumor progression via inducing EMT and collagen I fibers deposition.Oncotarget. 2015 Sep 22;6(28):25320-38. doi: 10.18632/oncotarget.4659. Oncotarget. 2015. PMID: 26318291 Free PMC article.
-
Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.Ann Hematol. 2014 Mar;93(3):485-492. doi: 10.1007/s00277-013-1939-2. Epub 2013 Oct 24. Ann Hematol. 2014. PMID: 24154679 Free PMC article.
-
Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.Oncotarget. 2015 Dec 29;6(42):44551-62. doi: 10.18632/oncotarget.6082. Oncotarget. 2015. PMID: 26575166 Free PMC article.
-
Deregulated expression of connective tissue growth factor (CTGF/CCN2) is linked to poor outcome in human cancer.Int J Cancer. 2015 Aug 1;137(3):504-11. doi: 10.1002/ijc.28972. Epub 2014 May 30. Int J Cancer. 2015. PMID: 24832082 Review.
-
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting.Cancer Metastasis Rev. 2025 Feb 13;44(1):32. doi: 10.1007/s10555-025-10248-4. Cancer Metastasis Rev. 2025. PMID: 39945880 Review.
Cited by
-
Identification of prognostic gene expression signatures based on the tumor microenvironment characterization of gastric cancer.Front Immunol. 2022 Aug 12;13:983632. doi: 10.3389/fimmu.2022.983632. eCollection 2022. Front Immunol. 2022. PMID: 36032070 Free PMC article.
-
Identification of key genes and pathways involved in T-DM1-resistance in OE-19 esophageal cancer cells through bioinformatics analysis.Heliyon. 2024 Sep 6;10(18):e37451. doi: 10.1016/j.heliyon.2024.e37451. eCollection 2024 Sep 30. Heliyon. 2024. PMID: 39309859 Free PMC article.
-
Pien Tze Huang Inhibits Migration and Invasion of Hepatocellular Carcinoma Cells by Repressing PDGFRB/YAP/CCN2 Axis Activity.Chin J Integr Med. 2024 Feb;30(2):115-124. doi: 10.1007/s11655-022-3533-8. Epub 2022 Aug 10. Chin J Integr Med. 2024. PMID: 35947230
-
Antiangiogenic Potential of an Olive Oil Extract: Insights from a Proteomic Study.J Agric Food Chem. 2024 Jun 12;72(23):13023-13038. doi: 10.1021/acs.jafc.3c08851. Epub 2024 May 29. J Agric Food Chem. 2024. PMID: 38809962 Free PMC article.
-
Mechanisms of breast cancer metastasis: the role of extracellular matrix.Mol Cell Biochem. 2025 May;480(5):2771-2796. doi: 10.1007/s11010-024-05175-x. Epub 2024 Dec 9. Mol Cell Biochem. 2025. PMID: 39652293 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous